Sanchez-Herrero et al. [91] analyzed ct-DNA profiling from 24 advanced ALK-rearranged NSCLC patients after the failure of ALK-i treatment: at least one ALK mutation was detected in 38.5% of plasma samples and the G1202R mutation emerged in four patients who progressed on alectinib or ceritinib. Here, ALK is linked to non-small cell lung carcinoma.